-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Immune-Onc Therapeutics, which specializes in the development of the "first-in-class" biological therapy drug, announced that IO-202, a research-based therapy developed by the company targeting white blood cell immunoglobulin-like subjects B4 (LILRB4, also known as ILT3), has completed the first patient administration in Phase 1 clinical studies.
Phase 1 clinical dose increment and amplification trial will assess the efficacy of IO-202 in treating patients with acute myeloid leukemia (AML) with monocyte differentiation and patients with chronic granulocytic leukemia (CMML).
AML is the most common acute leukemia in adults and is characterized by the proliferation of abnormal myelin cells (a type of white blood cell) in the bone marrow.
progress has been made in treatment, less than 30 per cent of AML patients are still alive within five years of their first diagnosis.
ISML is a cancer that starts in the bone marrow to make blood cells and invade the blood.
rare, with about 1,100 cases a year in the United States.
IO-202 is a "first-in-class" monoclonal antibody that blocks the signaling of the immunosuppressive liLRB4.
October 2018, Immune-Onc and the University of Texas published a groundbreaking study (DOI:10.1038/s41586-018-0615-z) that sheds light on the role of LILRB4 in AML immunosuppression and tumor immersion.
Preclinical studies have shown that IO-202 inhibits leukemia cell immersion by converting the "don't kill me" signal into a "kill me" signal, activating T cells to kill AML cells, and by converting the "don't find me" signal into a "find me" signal.
press release that this is the first T-cell activator to treat AML.
In addition to IO-202, Immune-Onc's research and development pipeline includes IO-108, an anti-LAIR1 antibody, and a variety of unexclosed in-study therapies targeting LILRB2 (also known as ILT4), as well as a variety of unreclosed tumors of solid tumors and hematoses.
Immune-Onc's research and development pipeline (Photo: Immune-Onc's official website) References: immune-Onc Therapeutics Announcs First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for The Treatment of Acute Myeloid Leukemia. Retrieved September 21, 2020, from . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .